Key points
- Millennium disclosed a 5.3% stake in Perspective Therapeutics (CATX) on July 20, about 6 million shares worth roughly $17.6M.
- Three weeks earlier the same fund reported 4.3%, so it bought about 1.1M more shares between June 23 and July 13.
- The form is a Schedule 13G, the passive kind. It signals no plan to push for changes at the company.
- CATX closed Monday at $2.92, about 23% below the $3.79 price of its $175M stock sale in February.
Twice in one month now, the hedge fund Millennium Management has filed ownership paperwork about the same small cancer-therapy company. That pattern is what pulled us into the filings. A second disclosure that quickly usually means the first one was already out of date, and in this case it was.
The company is Perspective Therapeutics (CATX). Monday's filing shows Millennium owning 5.3 percent of it, a stake worth somewhere around $17.6 million at the current share price.
Two filings, three weeks apart
The sequence goes like this. On June 30, Millennium reported holding 4.3 percent of Perspective, measured as of June 23. Monday's filing updates that to 5.3 percent as of July 13. Somewhere in those three weeks, the fund bought another million-plus shares and crossed the 5 percent mark, which is the point where securities law requires an owner to raise a hand in public.
The names on the paperwork are the usual Millennium trio: the management company and its parent entity, plus founder Israel Englander. Every Millennium disclosure lists the same three names, so that part is routine.
The form matters as much as the number
This is a Schedule 13G, which is the quiet version of an ownership disclosure. It is reserved for investors who certify they have no intention of influencing how the company is run. The loud version is a 13D, the form activist investors use when they want board seats or a sale. We wrote up the difference between the two forms if you want to go deeper on that.
With Millennium there is a second reason to stay calm about it. The firm runs money through many separate trading teams, and each team makes its own decisions. A stake this size is one team's idea. It is not a message from the top of the firm, and nobody should read it as Israel Englander personally championing radiopharmaceuticals. What it does tell you is narrower but still real: somebody inside one of the most competitive funds in the world liked this stock at 4.3 percent, then kept buying until they owned more than 5.
We saw a similar setup earlier this month, when Point72 disclosed a passive stake in Evommune (EVMN) right after a failed trial had crushed the stock. That piece is here, and the same caution applies to both: the filing shows what a fund owned on a single date and nothing about why.
What Perspective actually does
Perspective attaches a radioactive atom, lead-212, to molecules built to seek out tumor cells. When the lead decays, it gives off alpha particles, a heavy kind of radiation that travels only a cell or two before it stops. The goal is to concentrate the damage inside the tumor and spare nearly everything around it. The company has two cancer-specific programs in early clinical trials, one for neuroendocrine tumors and one for melanoma, plus a third aimed at a broader set of solid tumors. It also updated its corporate presentation on July 1 with progress across that pipeline and its plan to make the isotope regionally and deliver it straight to hospitals, since lead-212 decays too fast to sit in a warehouse.
Money is the other half of this story. In February, Perspective sold $175 million of new stock at $3.79 a share, in a deal the company said was oversubscribed. The stock closed Monday at $2.92, about 23 percent below what those February buyers paid. The 13G does not say what Millennium's team paid across June and July, so whether that buying has made or lost money so far is unknowable from the outside. That gap between what a filing shows and what people assume it shows is most of why we read them.
What we are watching next
Funds filing on Millennium's schedule generally update their ownership every quarter, so the next scheduled look at this stake is months away unless it grows enough to trigger an earlier amendment. Perspective also has a quarterly report expected at the end of July. In the meantime, what we actually know fits in one sentence: a sophisticated buyer went from 4.3 to 5.3 percent of a radiopharmaceutical company whose stock sits below its last fundraising price. If you are tempted to treat that as a signal all by itself, our piece on copying hedge fund disclosures covers why that has gone badly for people before. You can also follow the company's filings yourself on our CATX filings page.
Two filings in three weeks came from one team inside a firm that runs more than 340 of them. Our explainer on what a pod shop is covers why that matters when reading these.
